Table 2.

PFS KM-probability estimates in FL patients with confirmed relapse, stratified by method of relapse detection

Cohort	Group	N	Median Survival	1-Year Survival	3-Year Survival	5-Year Survival
LEAD	Clinical Detection	35	4.2 (2.5, 6)	94.3% (79%, 98.5%)	57.1% (39.3%, 71.5%)	40% (24.0%, 55.5%)
	Surveillance Detection	18	3.6 (1.8, 4.4)	94.4% (66.6%, 99.2%)	55.6% (30.5%, 74.8%)	22.2% (6.9%, 42.9%)
MER	Clinical Detection	63	2.0 (1.6, 2.6)	88.9% (78.1%, 94.5%)	33.3% (22.1%, 45.0%)	9.5% (3.9%, 18.2%)
	Surveillance Detection	50	2.4 (1.9, 2.8)	96.0% (84.9%, 99.0%)	32.0% (19.7%, 45.0%)	18.0% (8.9%, 29.7%)
Combined	Clinical Detection	98	2.5 (2, 3.2)	90.8% (83.1%, 95.1%)	41.8% (32.0%, 51.3%)	20.4% (13.1%, 28.9%)
	Surveillance Detection	68	2.5 (1.9, 2.9)	95.6% (86.9%, 98.6%)	38.2% (26.8%, 49.6%)	19.1% (10.8%, 29.2%)

PFS, progression-free survival, defined as the time from the date of diagnosis to the first date of clinical evaluation or imaging leading to subsequent relapse detection; clinical detection, defined by patient-reported symptoms at the time of confirmed detection of disease, concerning physical exam findings documented during a clinical visit, or abnormal lab values on prior follow-up; surveillance detection, defined by relapse of disease first suggested on imaging reviewed by a radiologist, as part of a routine surveillance schedule, and later confirmed by other diagnostic means.

Variables are presented as N and median survival in years or survival% (95% confidence interval) unless otherwise noted.

Abbreviations: KM, survival probability estimated using the Kaplan-Meir method; N, total number.